VEGFA and hepatocellular carcinoma: However, no improvement in tumor response or prognosis of patients was observed in HCC patients who received TACE and bevacizumab (a monoclonal antibody against VEGF), suggesting the complex neo‐angiogenic mechanisms after TACE 4, 5.